Threshold Pharmaceuticals, Inc. (NASDAQ:THLD)
| CAPS Rating |
|
|---|---|
| Open | $3.20 |
| Previous Close | $3.22 |
| Daily Range | $2.96 - $3.22 |
| 52-Week Range | $1.18 - $4.08 |
| Market Cap | $153.07M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 1,801,626 |
| Average Daily Volume | 0 |
THLD
VS S&P 500 (SPY)
How do you think THLD will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
THLD Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
THLD News and Commentary
- MKGAF-THLD Unite for Cancer Cure - Analyst Blog – NASDAQ
- Limit Your Risk: Smart Money Stock Picks in Strong Cash Positions – NASDAQ
- 3 Cancer-Fighting Stocks That Could Deliver Huge Gains – NASDAQ
- Smart Money Trends: 5 Biotech Stocks Being Bought Up By Insiders and Institutions – NASDAQ
- Low-Priced Biotech Stocks With Insider Buying – SeekingAlpha
- Undervalued Apricus Bio Poised to Follow Threshold Pharma in Receiving SPA Approval – SeekingAlpha
- 19 High Growth Micro Cap Stocks Under $10 – SeekingAlpha
- 8 Cancer Innovators to Watch – SeekingAlpha
- Amgen, Celgene and Novartis in the Fight Against Pancreatic Cancer – SeekingAlpha
- Hotel Sector Gainers for July 28: (MCS, OEH, RLH, GET, MHGC) – Blog at The Motley Fool
Related News and Articles
- Illuminating the Way Forward for Genomics – The Motley Fool
- When Passing Your Clinical Trial Isn't Enough – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
- Life Technologies' Sequence of Success – The Motley Fool
- Is Avanir Pharmaceuticals the Perfect Stock? – The Motley Fool
- Can Amgen Convince Docs to Recommend Approval? – The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
- Curing Diseases Makes For a Bad Business Model – The Motley Fool
RSS Headlines
Fool UK
